The India osteoarthritis therapeutics market was valued at USD 382.20 Million in 2024, driven by factors such as increasing healthcare awareness, rising osteoarthritis prevalence, and improvements in treatment options across the region. The market is expected to grow at a robust CAGR of 5.40% from 2025 to 2034, with projected values reaching USD 646.69 Million by 2034. This growth reflects the expansion of healthcare infrastructure, advancements in therapeutics, and a growing demand for effective osteoarthritis treatments across the country.
Base Year
Historical Period
Forecast Period
In March 2025, Dr. Reddy’s partnered with Bio-Thera to commercialize Stelara and Simponi biosimilars in Southeast Asia, potentially expanding biosimilar access for osteoarthritis treatment across emerging markets, including India.
A key trend in the India osteoarthritis therapeutics market is the rise of muscle-centric treatments. In January 2025, OPTM Healthcare's New Delhi clinic introduced AI-based diagnostics and phyto-topical therapies targeting joint degeneration and muscle health.
The rising prevalence of osteoarthritis in India is driving demand for effective therapeutics. Innovations in drug formulations and increasing healthcare access are also expected to propel market growth in the forecast period.
Value in USD Million
2025-2034
India Osteoarthritis Therapeutics Market Outlook
*this image is indicative*
Osteoarthritis therapeutics encompass a range of treatment approaches, including analgesics, nonsteroidal anti-inflammatory drugs, physical therapy, lifestyle modifications, and surgical options, to alleviate joint pain, enhance mobility, and slow disease progression. In India, the osteoarthritis therapeutics market is poised to grow at a CAGR of 5.40% during the forecast period of 2025–2034, due to the increasing elderly population, sedentary lifestyles, obesity, and greater awareness of early diagnosis.
High Osteoarthritis Prevalence to Accelerate Therapeutics Market Growth in India
A major growth driver in the market in India is the increasing prevalence of osteoarthritis, particularly among the aging and obese population. According to a study published by the National Institutes of Health (NIH) in March 2024, multiple studies across India reported osteoarthritis prevalence rates ranging from 20% to 40%. This significant and growing disease burden is expected to boost demand for effective treatment solutions, thereby driving sustained market expansion in the coming years.
Some of the notable trends include a rising emphasis on non-opioid pain relief for osteoarthritis.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Drug Class
Market Breakup by Dosage Form
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
NSAIDs to Account for a Significant Share for Segmentation by Drug Classes
The market, based on drug class, is divided into nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, other analgesics, hyaluronic acid injections, and others. NSAIDs are expected to dominate due to their proven efficacy in pain and inflammation management. Their accessibility, affordability, and role as a primary line of treatment make them the most utilized drug category in osteoarthritis therapeutics across the Indian pharmaceutical landscape.
The key features of the market report comprises epidemiology, clinical trials analysis, patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Headquartered in Mumbai, India, Sun Pharmaceutical Industries Ltd. was established in 1983. The company is actively involved in the osteoarthritis therapeutics market, notably through its MM-II candidate. This treatment has shown promising results in clinical trials, offering durable pain relief for knee osteoarthritis patients. The Phase 2b study demonstrated significant improvements, positioning MM-II as a potential alternative to existing treatments.
Dr. Reddy's Laboratories, established in 1984 and headquartered in Hyderabad, India, is a leading pharmaceutical company. In the osteoarthritis market, it has launched Hyalosyn, an intra-articular sodium hyaluronate injection aimed at providing relief for knee joint stiffness and immobility. Developed in collaboration with Gland Pharma, Hyalosyn addresses the growing demand for arthritis therapies in India, positioning Dr. Reddy’s as a key contributor to the market.
Cipla Limited, established in 1935 and headquartered in Mumbai, India, is a leading global pharmaceutical company. It has been actively involved in the India osteoarthritis therapeutics market, received approval for its generic version of Diclofenac sodium topical gel (1%), a therapeutic equivalent to Voltaren gel. This non-steroidal anti-inflammatory drug (NSAID) provides pain relief for osteoarthritis of joints such as the knees and hands, catering to the growing demand in India for affordable treatments.
Headquartered in Ahmedabad, India, and established in 1952, Zydus Lifesciences Limited has strengthened its presence in the market with the USFDA approval for its Ibuprofen and Famotidine Tablets (800 mg/26.6 mg) in February 2025. Indicated for osteoarthritis and rheumatoid arthritis, this formulation helps manage symptoms while reducing gastrointestinal risks. Produced at its Ahmedabad facility, the approval reflects Zydus's expanding therapeutic portfolio and growing global and domestic influence in musculoskeletal treatment solutions.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Aurobindo Pharma Ltd., Troikaa Pharmaceuticals Ltd., Meril Life Sciences Pvt. Ltd., and Lupin Ltd.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Class |
|
| Breakup by Dosage Form |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share